ArticleFrontiers in pharmacology2025
Dendrobine promotes bone formation via the canonical Wnt/β-catenin signaling pathway and prevents postmenopausal osteoporosis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In early postmenopausal women with sex steroid deficiency, an imbalance between bone resorption and bone formation causes an accelerated decline in bone mineral density due to a longer lifespan of osteoclasts and a shorter lifespan of osteoblasts. Given this context, dendrobine, as a primary bioactive alkaloid isolated from Objective: To investigate the anti-osteoporotic efficacy of dendrobine in increasing osteoblastogenesis and to elucidate the underlying mechanism. Methods: Using C3H/10T1/2 cells and human bone marrow-derived mesenchymal stromal cells, the effects of dendrobine on osteoblastogenesis and underlying mechanism were assayed by Western blotting, alkaline phosphatase staining, and quantitative polymerase chain reaction. The effectiveness of dendrobine in preventing postmenopausal osteoporosis was assessed using an ovariectomized mouse model by micro-computed tomography, H&E, alkaline phosphatase, and immunohistochemical staining. Results: In addition to inducing alkaline phosphatase, Runx2, osteocalcin, and Osterix expression in C3H/10T1/2 cells or human bone marrow-derived mesenchymal stromal cells, Dendrobine increased Runx2, alkaline phosphatase, and osteocalcin expression in ovariectomy (OVX) mice. Conclusion: In OVX mice, dendrobine attenuated the loss of cancellous bone, as shown in micro-computed tomography analysis. Dendrobine activated the Wnt/β-catenin pathway by suppressing the phosphorylation level of GSK-3β at Tyr216 site while keeping the level of β-catenin sustaining. This study suggests that dendrobine may be an effective treatment for postmenopausal osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.